感染是一种传染病，经验性治疗模式应该改变。
infection is an infectious disease and the empiric therapy paradigm should be changed.
作者信息
Li Hong, Yang Tiankuo, Tang Hong, Tang Xiaoqiong, Shen Yalin, Benghezal Mohammed, Tay Alfred, Marshall Barry
机构信息
West China Marshall Research Center for Infectious Diseases, Center of Infectious Diseases, Division of Infectious Diseases, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Helicobacter pylori Research Laboratory, School of Biomedical Sciences, Marshall Centre for Infectious Disease Research and Training, University of Western Australia, Nedlands, Australia.
出版信息
Precis Clin Med. 2019 Jun;2(2):77-80. doi: 10.1093/pcmedi/pbz009. Epub 2019 Jun 19.
Abstract
infection is an infectious disease. Given the alarmingly high antibiotic resistance in , gastroenterologists should change the empiric treatment paradigm to an antimicrobial susceptibility testing-guided precision treatment. Antimicrobial stewardship programs for should be implemented locally, regionally, and nationally to monitor the antibiotic resistance pattern.
摘要
感染是一种传染病。鉴于[具体地区]令人震惊的高抗生素耐药性，胃肠病学家应将经验性治疗模式转变为药敏试验指导的精准治疗。应在当地、区域和国家层面实施针对[具体地区]的抗菌药物管理计划，以监测抗生素耐药模式。
相似文献
1
infection is an infectious disease and the empiric therapy paradigm should be changed.感染是一种传染病，经验性治疗模式应该改变。
Precis Clin Med. 2019 Jun;2(2):77-80. doi: 10.1093/pcmedi/pbz009. Epub 2019 Jun 19.
2
Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment.随机对照试验：药敏指导治疗与经验铋四联疗法治疗幽门螺杆菌一线治疗。
Aliment Pharmacol Ther. 2019 Jun;49(11):1385-1394. doi: 10.1111/apt.15273. Epub 2019 Apr 24.
3
Primary Antimicrobial Susceptibility Changes in Children with Helicobacter pylori Infection over 13 Years in Northern Italy.意大利北部13年间幽门螺杆菌感染儿童的主要抗菌药物敏感性变化
Gastroenterol Res Pract. 2015;2015:717349. doi: 10.1155/2015/717349. Epub 2015 May 6.
4
Best Practices for Management.管理的最佳实践
Gastroenterol Hepatol (N Y). 2024 Mar;20(3):159-168.
5
Diagnosis and Treatment of Infection.感染的诊断与治疗
Annu Rev Med. 2022 Jan 27;73:183-195. doi: 10.1146/annurev-med-042220-020814.
6
Antimicrobial susceptibility testing for Helicobacter pylori in times of increasing antibiotic resistance.在抗生素耐药性不断增加的时代对幽门螺杆菌进行药敏试验。
World J Gastroenterol. 2014 Aug 7;20(29):9912-21. doi: 10.3748/wjg.v20.i29.9912.
7
Antimicrobial susceptibility testing before first-line treatment for infection in patients with dual or triple antibiotic resistance.对具有双重或三重抗生素耐药性的患者进行感染一线治疗前的抗菌药敏试验。
World J Gastroenterol. 2017 May 14;23(18):3367-3373. doi: 10.3748/wjg.v23.i18.3367.
8
Need for standardization and harmonization of Helicobacter pylori antimicrobial susceptibility testing.需要标准化和协调幽门螺杆菌抗菌药物敏感性测试。
Helicobacter. 2022 Apr;27(2):e12873. doi: 10.1111/hel.12873. Epub 2022 Feb 12.
9
Review article: the global emergence of Helicobacter pylori antibiotic resistance.综述文章：幽门螺杆菌抗生素耐药性在全球的出现
Aliment Pharmacol Ther. 2016 Feb;43(4):514-33. doi: 10.1111/apt.13497. Epub 2015 Dec 23.
10
Antibiotic-resistant Helicobacter pylori strains in Portuguese children.葡萄牙儿童中的耐抗生素幽门螺杆菌菌株
Pediatr Infect Dis J. 2005 May;24(5):404-9. doi: 10.1097/01.inf.0000160941.65324.6b.
引用本文的文献
1
First regional consensus on the management of infection in the Middle East.中东地区关于感染管理的首个区域共识。
World J Gastroenterol. 2025 Jul 21;31(27):107138. doi: 10.3748/wjg.v31.i27.107138.
2
An Update on Eradication of in Iran: A Review.伊朗根除[具体内容缺失]的最新情况：综述。
Middle East J Dig Dis. 2024 Jul;16(3):147-154. doi: 10.34172/mejdd.2024.389. Epub 2024 Jul 31.
3
Novel Drug-like HsrA Inhibitors Exhibit Potent Narrow-Spectrum Antimicrobial Activities against .新型类药性 HsrA 抑制剂对 表现出强效的窄谱抗菌活性。
Int J Mol Sci. 2024 Sep 22;25(18):10175. doi: 10.3390/ijms251810175.
4
Minocycline/Amoxicillin-Based Bismuth Quadruple Therapy for Eradication: A Pilot Study.基于米诺环素/阿莫西林的铋剂四联疗法根除幽门螺杆菌：一项试点研究。
Microorganisms. 2024 Feb 20;12(3):429. doi: 10.3390/microorganisms12030429.
5
Lipopolysaccharide O-antigen profiles of Helicobacter pylori strains from Southwest China.中国西南地区幽门螺杆菌菌株的脂多糖 O 抗原特征。
BMC Microbiol. 2023 Nov 22;23(1):360. doi: 10.1186/s12866-023-03116-0.
6
Antimicrobial Resistance Molecular Mechanisms of in Jordanian Children: A Cross-Sectional Observational Study.约旦儿童抗菌药物耐药性的分子机制：一项横断面观察性研究。
Antibiotics (Basel). 2023 Mar 20;12(3):618. doi: 10.3390/antibiotics12030618.
7
Editorial: Application of plant secondary metabolites to pain neuromodulation, volume III.社论：植物次生代谢产物在疼痛神经调节中的应用，第三卷。
Front Pharmacol. 2023 Feb 21;14:1166272. doi: 10.3389/fphar.2023.1166272. eCollection 2023.
8
Infection among Patients Attending the Gastroenterology Department in Tertiary Care Hospital, Kathmandu, Nepal.尼泊尔加德满都三级护理医院胃肠病科就诊患者中的感染情况。
Int J Microbiol. 2022 Nov 10;2022:1508473. doi: 10.1155/2022/1508473. eCollection 2022.
9
Editorial: Application of plant secondary metabolites to pain neuromodulation, volume II.社论：植物次生代谢产物在疼痛神经调节中的应用，第二卷。
Front Pharmacol. 2022 Sep 26;13:1013063. doi: 10.3389/fphar.2022.1013063. eCollection 2022.
10
The Potential Use of Antibiotics Against Helicobacter pylori Infection: Biopharmaceutical Implications.抗生素对幽门螺杆菌感染的潜在用途：生物制药意义
Front Pharmacol. 2022 Jun 27;13:917184. doi: 10.3389/fphar.2022.917184. eCollection 2022.
本文引用的文献
1
Role of Vonoprazan in Eradication Therapy in Japan.沃克在日本根除治疗中的作用。
Front Pharmacol. 2019 Jan 15;9:1560. doi: 10.3389/fphar.2018.01560. eCollection 2018.
2
Relative potency of proton-pump inhibitors, Helicobacter pylori therapy cure rates, and meaning of double-dose PPI.质子泵抑制剂的相对效力、幽门螺杆菌治疗的治愈率以及双倍剂量 PPI 的意义。
Helicobacter. 2019 Feb;24(1):e12554. doi: 10.1111/hel.12554. Epub 2018 Nov 15.
3
The Houston Consensus Conference on Testing for Helicobacter pylori Infection.
Clin Gastroenterol Hepatol. 2018 Dec;16(12):2004-2005. doi: 10.1016/j.cgh.2018.08.018. Epub 2018 Aug 13.
4
Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection.第五次全国幽门螺杆菌感染处理共识报告。
Helicobacter. 2018 Apr;23(2):e12475. doi: 10.1111/hel.12475. Epub 2018 Mar 7.
5
Helicobacter pylori infection and antibiotic resistance: a WHO high priority?幽门螺杆菌感染和抗生素耐药性：世卫组织的高度优先事项？
Nat Rev Gastroenterol Hepatol. 2017 Jul;14(7):383-384. doi: 10.1038/nrgastro.2017.57. Epub 2017 May 3.
6
Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis.全球幽门螺杆菌感染率：系统评价和荟萃分析。
Gastroenterology. 2017 Aug;153(2):420-429. doi: 10.1053/j.gastro.2017.04.022. Epub 2017 Apr 27.
7
Treating Helicobacter pylori effectively while minimizing misuse of antibiotics.有效治疗幽门螺杆菌，同时最大限度减少抗生素滥用。
Cleve Clin J Med. 2017 Apr;84(4):310-318. doi: 10.3949/ccjm.84a.14110.
8
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.美国胃肠病学会临床指南：幽门螺杆菌感染的治疗
Am J Gastroenterol. 2017 Feb;112(2):212-239. doi: 10.1038/ajg.2016.563. Epub 2017 Jan 10.
9
Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report.幽门螺杆菌感染的管理——马斯特里赫特 V/佛罗伦萨共识报告。
Gut. 2017 Jan;66(1):6-30. doi: 10.1136/gutjnl-2016-312288. Epub 2016 Oct 5.
10
The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults.《多伦多成人幽门螺杆菌感染治疗共识》。
Gastroenterology. 2016 Jul;151(1):51-69.e14. doi: 10.1053/j.gastro.2016.04.006. Epub 2016 Apr 19.
Zotero 插件